Abstract | BACKGROUND: OBJECTIVE: This review provides an overview of the use of omega-3 concentrates (both P-OM3 and over-the-counter fish oil) to lower triglycerides in people who have moderate hypertriglyceridemia ( triglycerides in the range of 150 - 500 mg/dl). The objectives were to examine clinical evidence, describe the magnitude of effects and predict future clinical use of P-OM3. METHODS: Published, peer-reviewed studies of omega-3 concentrates were included if they were placebo-controlled, double-blind, of sufficient size to demonstrate triglyceride lowering, and studied a population described as having a mean baseline triglyceride value of 150 - 500 mg/dl. Studies using the 4-g dose of P-OM3 were used to develop a model of percent triglyceride lowering as a function of baseline levels. RESULTS/CONCLUSIONS: P-OM3 are effective in reducing triglycerides by approximately 30% in this population and are likely to be combined with other drugs (e.g., statins) to treat combined dyslipidemia.
|
Authors | Ann C Skulas-Ray, Sheila G West, Michael H Davidson, Penny M Kris-Etherton |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 9
Issue 7
Pg. 1237-48
(May 2008)
ISSN: 1744-7666 [Electronic] England |
PMID | 18422480
(Publication Type: Journal Article, Review)
|
Chemical References |
- Fish Oils
- Docosahexaenoic Acids
- Eicosapentaenoic Acid
|
Topics |
- Coronary Disease
(drug therapy, etiology)
- Docosahexaenoic Acids
(adverse effects, pharmacology, therapeutic use)
- Eicosapentaenoic Acid
(adverse effects, pharmacology, therapeutic use)
- Fish Oils
(therapeutic use)
- Humans
- Hypertriglyceridemia
(drug therapy)
- Practice Guidelines as Topic
- Randomized Controlled Trials as Topic
- Risk Factors
- Severity of Illness Index
|